Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028

Why did the SEC drop its Binance lawsuit? How did Nvidia warn about China’s AI market? What impact will Trump tariffs court ruling have? Why is US-China trade talk stalled? How did the Fed's stagflation forecast affect markets? What caused Costco to beat sales despite tariffs? Why are Tesla and Elon Musk leaving Trump administration?

Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028

benzinga.com/general/biotech/25/05/45655477/analyst-bullish-on-ultragenyx-poised-for-growth-with-six-drug-approvals-expected-by-2028

On Wednesday, William Blair initiated coverage on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases.
Since 2017, the company has commercialized four products, which…

This story appeared on benzinga.com, 2025-05-28 19:22:39.